Mouwasat Medical Services Company (4002) Q4 2025 earnings summary

Executive summary

• Revenue increased to SR 3.22 billion in 2025, up from SR 2.88 billion in 2024, driven by growth in both medical services and pharmaceutical sales.

• Net profit rose to SR 852 million in 2025, compared to SR 670 million in 2024, with EPS at SR 4.11 versus SR 3.23 year-over-year.

• Gross profit improved to SR 1.36 billion, reflecting higher volumes and operational efficiency.

• The group expanded its asset base to SR 5.99 billion, with significant investments in property, equipment, and new hospital projects.

Financial highlights

• Medical services revenue reached SR 2.74 billion, and pharmaceutical sales SR 487 million in 2025.

• Gross margin was 42.3% in 2025, up from 42.9% in 2024.

• Operating profit increased to SR 880 million, up from SR 724 million year-over-year.

• Cash flow from operations was SR 1.18 billion, with cash and equivalents at SR 497 million at year-end.

• Total dividends declared for 2025 amounted to SR 425 million.

Outlook and guidance

• Management expects continued growth from new hospital openings and expansion projects.

• Capital commitments of SR 239 million are allocated for ongoing and future expansion.

• No significant subsequent events were reported after year-end.